MiR-200c and HuR in ovarian cancer
暂无分享,去创建一个
Enrica Martinelli | Giovanni Scambia | E. Martinelli | G. Scambia | G. Ferrandina | C. Ferlini | S. Shahabi | Shohreh Shahabi | Marisa Mariani | Cristiano Ferlini | Giuseppina Raspaglio | Gabriella Ferrandina | Silvia Prislei | Steven Sieber | M. Mariani | G. Raspaglio | S. Prislei | S. Sieber
[1] E. Martinelli,et al. Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.
[2] S. Vasudevan,et al. Post-transcriptional stimulation of gene expression by microRNAs. , 2013, Advances in experimental medicine and biology.
[3] Uwe Ohler,et al. Integrative regulatory mapping indicates that the RNA-binding protein HuR couples pre-mRNA processing and mRNA stability. , 2011, Molecular cell.
[4] E. Martinelli,et al. Class III β‐tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer , 2012, Journal of cellular physiology.
[5] J. Steitz,et al. AU-Rich-Element-Mediated Upregulation of Translation by FXR1 and Argonaute 2 , 2007, Cell.
[6] C. Croce,et al. MicroRNA signatures in human ovarian cancer. , 2007, Cancer research.
[7] Jae Hoon Kim,et al. MicroRNA Expression Profiles in Serous Ovarian Carcinoma , 2008, Clinical Cancer Research.
[8] Enrica Calura,et al. Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections. , 2011, The Lancet. Oncology.
[9] Simone Brabletz,et al. The ZEB/miR‐200 feedback loop—a motor of cellular plasticity in development and cancer? , 2010, EMBO reports.
[10] E. Berns,et al. Integrated genomics of chemotherapy resistant ovarian cancer: a role for extracellular matrix, TGFbeta and regulating microRNAs. , 2010, The international journal of biochemistry & cell biology.
[11] G. Scambia,et al. Molecular mechanisms of patupilone resistance. , 2008, Cancer research.
[12] E. Pasquier,et al. Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer. , 2007, Cancer research.
[13] R. Agami,et al. MicroRNA regulation by RNA-binding proteins and its implications for cancer , 2011, Nature Reviews Cancer.
[14] E. Berns,et al. MicroRNAs in ovarian cancer biology and therapy resistance. , 2010, The international journal of biochemistry & cell biology.
[15] G. Campiani,et al. The seco-taxane IDN5390 is able to target class III beta-tubulin and to overcome paclitaxel resistance. , 2004, Cancer research.
[16] S. Rosenwald,et al. Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients. , 2009, Gynecologic oncology.
[17] W. Filipowicz,et al. The widespread regulation of microRNA biogenesis, function and decay , 2010, Nature Reviews Genetics.
[18] Georgia Salanti,et al. Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments. , 2006, Journal of the National Cancer Institute.
[19] E. Martinelli,et al. HuR regulates beta-tubulin isotype expression in ovarian cancer. , 2010, Cancer research.
[20] B. Martínez-Delgado,et al. The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients. , 2010, Endocrine-Related Cancer.
[21] Zhihui Feng,et al. A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. , 2009, Gynecologic oncology.
[22] G. Song,et al. Role of hypoxia in the hallmarks of human cancer , 2009, Journal of cellular biochemistry.
[23] R. Broaddus,et al. Restoration of miR-200c to Ovarian Cancer Reduces Tumor Burden and Increases Sensitivity to Paclitaxel , 2012, Molecular Cancer Therapeutics.
[24] E. Pasquier,et al. Class III β-Tubulin Mediates Sensitivity to Chemotherapeutic Drugs in Non–Small Cell Lung Cancer , 2007 .
[25] C. Croce. Causes and consequences of microRNA dysregulation in cancer , 2009, Nature Reviews Genetics.
[26] E. Howe,et al. Loss of miR-200c: A Marker of Aggressiveness and Chemoresistance in Female Reproductive Cancers , 2009, Journal of oncology.
[27] E. Martinelli,et al. Class III β-Tubulin Overexpression Is a Marker of Poor Clinical Outcome in Advanced Ovarian Cancer Patients , 2006, Clinical Cancer Research.
[28] Kotb Abdelmohsen,et al. Posttranscriptional regulation of cancer traits by HuR , 2010, Wiley interdisciplinary reviews. RNA.
[29] G. Scambia,et al. Hypoxia induces class III beta-tubulin gene expression by HIF-1alpha binding to its 3' flanking region. , 2008, Gene.
[30] S. Nordeen,et al. MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents , 2009, Molecular Cancer Therapeutics.